LEVAQUIN TABS

Compare LEVAQUIN TABS  to:
Compare
Compare

Generic Name for LEVAQUIN TABS

Levofloxacin 250mg, 500mg, 750mg.

Legal Classification:

Rx

Pharmacological Class for LEVAQUIN TABS

Quinolone.

Manufacturer of LEVAQUIN TABS

PriCara

Indications for LEVAQUIN TABS

Susceptible bacterial infections including acute sinusitis, acute exacerbations of chronic bronchitis, nosocomial or community-acquired pneumonia (CAP), UTIs, acute pyelonephritis, chronic bacterial prostatitis, skin and skin structure infections. Inhalation anthrax (post-exposure): to reduce incidence or progression of disease (see literature).

Adult dose for LEVAQUIN TABS

≥18yrs: Regimen depends on pathogen type (see literature). Tabs: take with water. Oral soln: take on empty stomach. IV: infuse over 60 minutes (250mg or 500mg), or over 90 minutes (750mg). Bronchitis: 500mg once daily for 7 days. Nosocomial pneumonia: 750mg once daily for 7–14 days. CAP: 500mg once daily for 7–14 days or 750mg once daily for 5 days. Sinusitis: 500mg once daily for 10–14 days or 750mg once daily for 5 days. Uncomplicated skin and skin structure: 500mg once daily for 7–10 days; complicated: 750mg once daily for 7–14 days. Prostatitis: 500mg once daily for 28 days. Uncomplicated UTIs: 250mg once daily for 3 days. Complicated UTIs, acute pyelonephritis: 250mg once daily for 10 days or 750mg once daily for 5 days. Postexposure inhalational anthrax: 500mg once daily for 60 days (start as soon as possible after exposure). Renal impairment (CrCl <50mL/min): reduce dose; see literature.

Children's dosing for LEVAQUIN TABS

Inhalation anthrax (post–exposure): ≥6months: <50kg: 8mg/kg twice daily for 60 days; max 250mg/dose. >50kg: 500mg once daily for 60 days;

Also:

Warnings/Precautions for LEVAQUIN TABS

Increased risk of tendinitis and tendon rupture esp. in patients >60yrs, or those with kidney, heart or lung transplants. Maintain adequate hydration. Renal impairment. CNS disorders (eg, cerebral arteriosclerosis, epilepsy) that increase seizure risk. Avoid in proarrhythmic conditions (eg, bradycardia, cardiomyopathy) or hypokalemia. Discontinue if rash, jaundice, other signs of hypersensitivity, hypoglycemic reactions, phototoxicity, CNS stimulation, or hepatitis occurs. Discontinue if tendon pain, inflammation or rupture occurs. Monitor blood, renal, hepatic, and hematopoietic function. Reevaluate if peripheral neuropathy occurs. Avoid excessive sun or UV light. Pregnancy (Cat.C), nursing mothers: not recommended.

Interactions for LEVAQUIN TABS

Avoid drugs that prolong QT interval (eg, Class IA or Class III antiarrhythmics). Avoid oral form with antacids containing magnesium or aluminum, sucralfate, didanosine, iron, zinc, other metal cations (separate dosing by at least 2 hours). Increased risk of tendinitis and tendon rupture with corticosteroids. Monitor theophylline, warfarin, antidiabetic agents. Caution with other drugs that may lower seizure threshold (eg, NSAIDs).

Adverse Reactions for LEVAQUIN TABS

GI upset, CNS stimulation, dizziness, headache, pruritus, rash, abdominal pain, tendinitis/rupture, local reactions (inj); rarely: peripheral neuropathy, hepatotoxicity, photosensitivity, convulsions. Children: also musculoskeletal disorders.

How is LEVAQUIN TABS supplied?

Tabs 250mg, 500mg—50
750mg—20
LEVA-Pak (5 x 750mg tabs)—1
Oral soln—480mL
Inj conc (single-use vials) 20mL, 30mL—1
Inj premixed 50mL, 100mL, 150mL—1

Related Disease:

Bronchitis, chronic
Infections, bacterial~systemic antiinfectives
Pneumonia
Sinusitis

Related Resources

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions